Should You Buy OHB Pediatrics Before the SPAC Merger Closes?
OHB Pediatrics, which trades as Oak Hill Bio, is going public through a merger with Research Alliance Corp III (Nasdaq: RACC) and expects to close by year-end 2026. The setup offers a Phase 3 rare-disease asset and committed financing, but shareholders should watch redemption risk and heavy dilution closely.
OHB Pediatrics, which trades as Oak Hill Bio, is going public through a merger with Research Alliance Corp III (Nasdaq: RACC) and expects to close by year-end 2026. The setup offers a Phase 3 rare-disease asset and committed financing, but shareholders should watch redemption risk and heavy dilution closely.
Deal at a Glance
SPAC partner: Research Alliance Corp III
SPAC ticker (trades now): RACC
Expected post-merger ticker: OAKH
Implied valuation: $193M EV
Expected close: Q4 2026
Est. first trading date: late Q4 2026
Deal status: Announced
Source filing: SEC 425 (2026-07-28)
Company Overview
OHB Pediatrics Ltd. is the legal name of the business, and it says it trades as Oak Hill Bio. It is a clinical-stage rare disease biotechnology company focused on acquiring and developing therapeutics for rare diseases with significant unmet need that have been deprioritized by large pharma. Its lead program is rugonersen (OHB-724), an antisense oligonucleotide in Phase 3 development for Angelman syndrome.
The company says it was formed in 2024 as a subsidiary of Oak Hill Bio Holdings, formerly Oak Hill Bio Ltd. The first patient in the pivotal BEACON Phase 3 trial was dosed in July 2026, which makes this a development-stage story rather than a commercial one. Angelman syndrome is the core market here: the company says it affects about 30,000 diagnosed patients in the U.S. and EU5 and currently has no approved disease-modifying therapies. The deck frames the opportunity around rare-disease dynamics such as concentrated treatment centers, high diagnosis intensity, and chronic treatment potential.
The SPAC Deal
OHB Pediatrics is merging with Research Alliance Corp III, a SPAC that currently trades as RACC. The combined company is expected to trade on Nasdaq Capital Market under the new ticker OAKH, and the company will be renamed Oak Hill Bio, Inc. at closing. The deal is still announced, not closed, and the parties say they expect to close by year-end 2026, subject to shareholder and regulatory approvals. Based on that timing, the first trading window is likely late Q4 2026 if the process stays on track.
The investor deck gives the clearest valuation math: $160 million pre-money equity value for OHB and $193 million enterprise value after subtracting pro forma cash, with an illustrative pro forma equity value of $353 million. The deck says the $160 million pre-money figure is OHB’s fully diluted equity value, including Roche’s equity interest tied to the rugonersen license. On the cash side, RACC had $75 million in trust as of May 31, 2026, plus about $2 million of interest assumed, for about $77 million of cash at close assuming no redemptions. That is the key SPAC risk: the deck explicitly warns that significant redemptions could materially impact cash position and runway.
The financing package is larger than the trust alone. The deal includes $100 million of committed private financing, with $45 million funded at signing through a SAFE from RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund IV, L.P., and the remaining $55 million expected at closing through an oversubscribed PIPE at $10.00 per share. Named PIPE participants include Balyasny Asset Management, Janus Henderson Investors, KCap Biotechnology Fund, venBio, ADAR1 Capital Management, Affinity Asset Advisors, Ally Bridge Group, BVF Partners, Great Point Partners, Logos Capital, SilverArc Capital, and Trails Edge Capital Partners. The sponsor also agreed to backstop redemptions dollar-for-dollar up to $75 million by buying Class A shares or pre-funded warrants at $10.00 per share. Dilution is meaningful: the deck highlights founder shares, sponsor shares, PIPE shares, SAFE conversion, and future equity issuances after closing.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The stated use of proceeds is to fund development through the Phase 3 readout and potential NDA submission in 2H 2029. The company says the transaction, together with Oak Hill Bio’s recent $32.5 million Series A, is expected to provide cash runway through that point. For a clinical-stage biotech, that matters because the capital need is front-loaded long before any product revenue arrives.
The SPAC route also gives the company a faster path to the public markets than a traditional IPO and lets it present forward-looking development plans in the investor materials. The sponsor backing and committed private financing are part of the pitch: the deal is designed to reduce financing uncertainty while keeping enough capital in place to advance a Phase 3 rare-disease program.
Financial Highlights
OHB is pre-revenue in the materials reviewed, and no product revenue is disclosed. The business is being valued on pipeline progress rather than current sales, with the BEACON Phase 3 trial for Angelman syndrome as the main operating milestone. The deck and press release emphasize that rugonersen is already in Phase 3, which is more advanced than many de-SPAC biotech stories.
The company says the financing package should support operations through Phase 3 readout and a potential NDA submission in 2H 2029, but the deck also says Oak Hill Bio will need substantial additional funding to advance current and future candidates. No historical revenue, margins, or current cash balance for OHB were disclosed in the surfaced materials. Investors should treat the runway guidance as a forward projection, not a guarantee.
Risk Factors
The biggest de-SPAC-specific risk is redemptions. RACC had $75 million in trust as of May 31, 2026, plus about $2 million of interest assumed, but the deck warns that significant redemptions could materially reduce cash and runway. Even with the sponsor backstop and PIPE, a weak redemption outcome would change the capital structure and the amount of money available to fund the trial.
Dilution is another major issue. The structure includes founder shares, sponsor shares, PIPE shares, SAFE conversion, and potential future equity issuances, all of which can pressure per-share value after closing. Beyond the SPAC mechanics, this is a clinical-stage biotech with binary development risk: rugonersen still has to succeed in Phase 3, clear regulatory review, and eventually be commercialized. The deal can also fail if shareholder approval, regulatory approvals, or other closing conditions are not met, and Nasdaq listing or post-close liquidity risk is explicitly disclosed.
Comparable Public Companies
The closest public peers by modality and indication are Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Ultragenyx (RARE), PTC Therapeutics (PTCT), and BioMarin (BMRN). This is not a perfect comp set, but it is the right neighborhood for a rare-disease, neurology-adjacent, ASO-driven story.
The filing materials do not include a formal trading multiple table or current market data, so there is no disclosed valuation range to anchor against live comps here. Qualitatively, the public market tends to reward rare-disease names with late-stage assets and visible commercial paths, while punishing programs that are still far from approval. OHB sits in the middle: Phase 3 is a real milestone, but it is still a pre-revenue biotech with meaningful execution risk.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
The setup favors investors who want a late-stage rare-disease biotech story with real clinical momentum and committed financing, but the SPAC mechanics matter just as much as the science. The key question is not whether OHB has an interesting asset; it is whether the deal closes with enough trust cash left after redemptions and whether the post-close share count leaves enough upside per share.
Shareholders should watch three things as the vote approaches: redemption levels, final PIPE participation, and whether the company keeps its year-end 2026 close target. This matters now because the deal combines a Phase 3 Angelman syndrome program, a $160 million pre-money valuation, and a structure built to deliver capital quickly. If the financing holds together, OAKH could enter the market with a credible runway; if redemptions are heavy, the economics get much less attractive.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
